Management of Acute Ischemic Coronary Syndromes: The Present and Future

This article begins by discussing the pathogenesis of acute ischemic syndromes reviewing the cascade of ischemic events. We then go on to discuss the interventional management of acute ischemic syndromes and the benefits of early conservative therapy versus aggressive management with either PTCA or stenting. A discussion is then held regarding the pharmacological management of acute ischemic syndromes including the various agents involved including thrombolytic agents, aspirin, heparin and other measures. The main body of the article reviews the role of the 2B/3A inhibitors and the management of acute ischemic syndromes, including those studies that have been conducted to date, reviewing the role of the 2B/3A inhibitors and acute ischemic syndromes and the outcome from their application.